PL3315131T3 - Środek terapeutyczny w zwłóknieniu - Google Patents
Środek terapeutyczny w zwłóknieniuInfo
- Publication number
- PL3315131T3 PL3315131T3 PL16814513.4T PL16814513T PL3315131T3 PL 3315131 T3 PL3315131 T3 PL 3315131T3 PL 16814513 T PL16814513 T PL 16814513T PL 3315131 T3 PL3315131 T3 PL 3315131T3
- Authority
- PL
- Poland
- Prior art keywords
- fibrosis
- therapeutic agent
- therapeutic
- agent
- Prior art date
Links
- 206010016654 Fibrosis Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 230000004761 fibrosis Effects 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015127788 | 2015-06-25 | ||
| PCT/JP2016/068902 WO2016208744A1 (ja) | 2015-06-25 | 2016-06-24 | 線維症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3315131T3 true PL3315131T3 (pl) | 2022-12-12 |
Family
ID=57585165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16814513.4T PL3315131T3 (pl) | 2015-06-25 | 2016-06-24 | Środek terapeutyczny w zwłóknieniu |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10449189B2 (pl) |
| EP (2) | EP3315131B1 (pl) |
| JP (3) | JP6974167B2 (pl) |
| KR (1) | KR102647942B1 (pl) |
| CN (2) | CN107708697B (pl) |
| AU (1) | AU2016284531B2 (pl) |
| BR (1) | BR112017028137B1 (pl) |
| CA (1) | CA2990791A1 (pl) |
| DK (1) | DK3315131T3 (pl) |
| ES (1) | ES2928684T3 (pl) |
| HU (1) | HUE060732T2 (pl) |
| MA (1) | MA42266A (pl) |
| MX (2) | MX381792B (pl) |
| MY (1) | MY191219A (pl) |
| PH (1) | PH12017502322B1 (pl) |
| PL (1) | PL3315131T3 (pl) |
| PT (1) | PT3315131T (pl) |
| RU (1) | RU2729630C2 (pl) |
| SG (2) | SG10201912684TA (pl) |
| WO (1) | WO2016208744A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007139608A1 (en) | 2006-03-14 | 2007-12-06 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| US12152246B2 (en) | 2006-03-14 | 2024-11-26 | Ceres, Inc. | Nucleotide sequences and corresponding polypeptides conferring modulated growth rate and biomass in plants grown in saline conditions |
| PT3583943T (pt) | 2017-02-15 | 2024-10-15 | Taiho Pharmaceutical Co Ltd | Composição farmacêutica |
| JP7074760B2 (ja) | 2017-09-08 | 2022-05-24 | 大鵬薬品工業株式会社 | 抗腫瘍剤及び抗腫瘍効果増強剤 |
| WO2020059744A1 (ja) | 2018-09-18 | 2020-03-26 | 大鵬薬品工業株式会社 | アシルチオウレア化合物とアビラテロンの併用療法 |
| TWI872203B (zh) * | 2020-02-14 | 2025-02-11 | 日商大鵬藥品工業股份有限公司 | 醯基硫脲化合物的製造方法 |
| CN115177636A (zh) * | 2022-07-18 | 2022-10-14 | 陕西科美致尚生物科技有限公司 | 一种用于治疗前列腺钙化的组合物及其制备方法与应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2313777T3 (es) | 1998-04-28 | 2009-03-01 | Toshikazu Nakamura | Inhibidores de la neovascularizacion. |
| JP2003238592A (ja) | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| MX2007015679A (es) | 2005-06-30 | 2008-02-21 | Amgen Inc | Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer. |
| CA2630884A1 (en) | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| CN101360748B (zh) * | 2005-11-30 | 2012-05-30 | 沃泰克斯药物股份有限公司 | c-MET抑制剂及其应用 |
| US8314087B2 (en) | 2007-02-16 | 2012-11-20 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and methods of use |
| WO2009053737A2 (en) | 2007-10-25 | 2009-04-30 | Astrazeneca Ab | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders |
| SI2287155T1 (sl) | 2008-04-10 | 2013-10-30 | Taiho Pharmaceutical Co., Ltd. | Aciltiosečninska spojina ali njena sol in njena uporaba |
| UY32049A (es) * | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| BR112012019302B1 (pt) * | 2010-02-03 | 2022-06-21 | Incyte Holdings Corporation | Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula |
| EA025281B9 (ru) | 2010-05-17 | 2017-08-31 | Инкозен Терапьютикс Пвт. Лтд. | СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| RU2494470C1 (ru) * | 2012-04-04 | 2013-09-27 | Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "Саентифик Фьючер Менеджмент") | Способ лечения фиброза легких |
| US9149471B2 (en) | 2013-09-30 | 2015-10-06 | National University Corporation Tokyo University Of Agriculture And Technology | Therapeutic agent for osteoporosis |
-
2016
- 2016-06-24 MA MA042266A patent/MA42266A/fr unknown
- 2016-06-24 HU HUE16814513A patent/HUE060732T2/hu unknown
- 2016-06-24 EP EP16814513.4A patent/EP3315131B1/en active Active
- 2016-06-24 CA CA2990791A patent/CA2990791A1/en active Pending
- 2016-06-24 MX MX2017016774A patent/MX381792B/es unknown
- 2016-06-24 CN CN201680037175.7A patent/CN107708697B/zh active Active
- 2016-06-24 SG SG10201912684TA patent/SG10201912684TA/en unknown
- 2016-06-24 BR BR112017028137-6A patent/BR112017028137B1/pt active IP Right Grant
- 2016-06-24 JP JP2017525457A patent/JP6974167B2/ja active Active
- 2016-06-24 WO PCT/JP2016/068902 patent/WO2016208744A1/ja not_active Ceased
- 2016-06-24 US US15/574,060 patent/US10449189B2/en active Active
- 2016-06-24 RU RU2017145271A patent/RU2729630C2/ru active
- 2016-06-24 MY MYPI2017704204A patent/MY191219A/en unknown
- 2016-06-24 PT PT168145134T patent/PT3315131T/pt unknown
- 2016-06-24 SG SG11201709260TA patent/SG11201709260TA/en unknown
- 2016-06-24 KR KR1020177033481A patent/KR102647942B1/ko active Active
- 2016-06-24 AU AU2016284531A patent/AU2016284531B2/en active Active
- 2016-06-24 EP EP21205221.1A patent/EP3973962A1/en not_active Withdrawn
- 2016-06-24 ES ES16814513T patent/ES2928684T3/es active Active
- 2016-06-24 CN CN202110067291.6A patent/CN112716952A/zh active Pending
- 2016-06-24 DK DK16814513.4T patent/DK3315131T3/da active
- 2016-06-24 PL PL16814513.4T patent/PL3315131T3/pl unknown
- 2016-06-24 PH PH1/2017/502322A patent/PH12017502322B1/en unknown
-
2017
- 2017-12-19 MX MX2020012989A patent/MX2020012989A/es unknown
-
2019
- 2019-09-17 US US16/573,362 patent/US10695340B2/en active Active
-
2020
- 2020-06-02 US US16/889,870 patent/US11191759B2/en active Active
-
2021
- 2021-10-29 US US17/513,946 patent/US11690838B2/en active Active
- 2021-11-04 JP JP2021180108A patent/JP7258985B2/ja active Active
-
2023
- 2023-04-05 JP JP2023061284A patent/JP7498827B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250685A0 (en) | Medicinal substance induces cytotoxicity | |
| SG10201912416QA (en) | Therapeutic agents | |
| IL266530A (en) | Fibrosis treatment | |
| GB201509893D0 (en) | Therapeutic agents | |
| GB201517263D0 (en) | Therapeutic agents | |
| GB201410816D0 (en) | Therapeutic agents | |
| GB201603104D0 (en) | Therapeutic agents | |
| SG10201912684TA (en) | Therapeutic agent for fibrosis | |
| GB201509885D0 (en) | Therapeutic agents | |
| GB201502412D0 (en) | Therapeutic use | |
| GB201410817D0 (en) | Therapeutic agents | |
| IL253617A0 (en) | Snekribirock for the treatment of leprosy | |
| GB201410815D0 (en) | Therapeutic agents | |
| GB201509888D0 (en) | Therapeutic agents | |
| IL272271A (en) | A therapeutic agent for fibrosis | |
| IL250160A0 (en) | medicinal substance | |
| GB201513299D0 (en) | Therapeutic agents | |
| GB201521767D0 (en) | Therapeutic agents | |
| GB201517264D0 (en) | Therapeutic agents | |
| SG11201705915VA (en) | Therapeutic agent for ischemic diseases | |
| SG11201700059WA (en) | Therapeutic agent for keratoconjunctive disorder | |
| GB201506786D0 (en) | Therapeutic use | |
| GB201616563D0 (en) | Therapeutic agents | |
| GB201911521D0 (en) | Therapeutic agent | |
| GB201516109D0 (en) | Therapeutic agent |